Abstract

Clinical heterogeneity is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways like mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-Erk) signaling plays a role in the heterogeneous clinical outcome of CLL patients. In this study, we have investigated the role of Sprouty (SPRY)2 as a negative regulator of receptor and nonreceptor tyrosine kinase signaling in the pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL cells, particularly from poor-prognosis patients compared with those from good-prognosis patients. Overexpression of SPRY2 in CLL cells from poor-prognosis patients increased their apoptosis. Conversely, downregulation of SPRY2 in CLL cells from good-prognosis patients resulted in increased proliferation. Furthermore, CLL cells with low SPRY2 expression grew more rapidly in a xenograft model of CLL. Strikingly, B-cell-specific transgenic overexpression of spry2 in mice led to a decrease in the frequency of B1 cells, the precursors of CLL cells in rodents. Mechanistically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding to and antagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL cells. We also show that SPRY2 is targeted by microRNA-21, which in turn leads to increased activity of Syk and Erk in CLL cells. Taken together, these results establish SPRY2 as a critical negative regulator of BCR-mediated MAPK-Erk signaling in CLL, thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of CLL.

Original languageEnglish (US)
Pages (from-to)2310-2321
Number of pages12
JournalBlood
Volume127
Issue number19
DOIs
StatePublished - May 12 2016

Fingerprint

Extracellular Signal-Regulated MAP Kinases
B-Cell Chronic Lymphocytic Leukemia
Mitogen-Activated Protein Kinases
B-Lymphocytes
Cells
Protein-Tyrosine Kinases
MicroRNAs
Heterografts
Chemical activation
Apoptosis
Receptor Protein-Tyrosine Kinases
Rodentia
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Sprouty 2 : A novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. / Shukla, Ashima; Rai, Karan; Shukla, Vipul; Chaturvedi, Nagendra K.; Bociek, Robert G; Pirruccello, Samuel Jay; Band, Hamid; Lu, Runqing; Joshi, Shantaram S.

In: Blood, Vol. 127, No. 19, 12.05.2016, p. 2310-2321.

Research output: Contribution to journalArticle

Shukla, Ashima ; Rai, Karan ; Shukla, Vipul ; Chaturvedi, Nagendra K. ; Bociek, Robert G ; Pirruccello, Samuel Jay ; Band, Hamid ; Lu, Runqing ; Joshi, Shantaram S. / Sprouty 2 : A novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. In: Blood. 2016 ; Vol. 127, No. 19. pp. 2310-2321.
@article{4d24a21beda74db3b3caded3f1148249,
title = "Sprouty 2: A novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL",
abstract = "Clinical heterogeneity is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways like mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-Erk) signaling plays a role in the heterogeneous clinical outcome of CLL patients. In this study, we have investigated the role of Sprouty (SPRY)2 as a negative regulator of receptor and nonreceptor tyrosine kinase signaling in the pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL cells, particularly from poor-prognosis patients compared with those from good-prognosis patients. Overexpression of SPRY2 in CLL cells from poor-prognosis patients increased their apoptosis. Conversely, downregulation of SPRY2 in CLL cells from good-prognosis patients resulted in increased proliferation. Furthermore, CLL cells with low SPRY2 expression grew more rapidly in a xenograft model of CLL. Strikingly, B-cell-specific transgenic overexpression of spry2 in mice led to a decrease in the frequency of B1 cells, the precursors of CLL cells in rodents. Mechanistically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding to and antagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL cells. We also show that SPRY2 is targeted by microRNA-21, which in turn leads to increased activity of Syk and Erk in CLL cells. Taken together, these results establish SPRY2 as a critical negative regulator of BCR-mediated MAPK-Erk signaling in CLL, thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of CLL.",
author = "Ashima Shukla and Karan Rai and Vipul Shukla and Chaturvedi, {Nagendra K.} and Bociek, {Robert G} and Pirruccello, {Samuel Jay} and Hamid Band and Runqing Lu and Joshi, {Shantaram S}",
year = "2016",
month = "5",
day = "12",
doi = "10.1182/blood-2015-09-669317",
language = "English (US)",
volume = "127",
pages = "2310--2321",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Sprouty 2

T2 - A novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

AU - Shukla, Ashima

AU - Rai, Karan

AU - Shukla, Vipul

AU - Chaturvedi, Nagendra K.

AU - Bociek, Robert G

AU - Pirruccello, Samuel Jay

AU - Band, Hamid

AU - Lu, Runqing

AU - Joshi, Shantaram S

PY - 2016/5/12

Y1 - 2016/5/12

N2 - Clinical heterogeneity is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways like mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-Erk) signaling plays a role in the heterogeneous clinical outcome of CLL patients. In this study, we have investigated the role of Sprouty (SPRY)2 as a negative regulator of receptor and nonreceptor tyrosine kinase signaling in the pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL cells, particularly from poor-prognosis patients compared with those from good-prognosis patients. Overexpression of SPRY2 in CLL cells from poor-prognosis patients increased their apoptosis. Conversely, downregulation of SPRY2 in CLL cells from good-prognosis patients resulted in increased proliferation. Furthermore, CLL cells with low SPRY2 expression grew more rapidly in a xenograft model of CLL. Strikingly, B-cell-specific transgenic overexpression of spry2 in mice led to a decrease in the frequency of B1 cells, the precursors of CLL cells in rodents. Mechanistically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding to and antagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL cells. We also show that SPRY2 is targeted by microRNA-21, which in turn leads to increased activity of Syk and Erk in CLL cells. Taken together, these results establish SPRY2 as a critical negative regulator of BCR-mediated MAPK-Erk signaling in CLL, thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of CLL.

AB - Clinical heterogeneity is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways like mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-Erk) signaling plays a role in the heterogeneous clinical outcome of CLL patients. In this study, we have investigated the role of Sprouty (SPRY)2 as a negative regulator of receptor and nonreceptor tyrosine kinase signaling in the pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL cells, particularly from poor-prognosis patients compared with those from good-prognosis patients. Overexpression of SPRY2 in CLL cells from poor-prognosis patients increased their apoptosis. Conversely, downregulation of SPRY2 in CLL cells from good-prognosis patients resulted in increased proliferation. Furthermore, CLL cells with low SPRY2 expression grew more rapidly in a xenograft model of CLL. Strikingly, B-cell-specific transgenic overexpression of spry2 in mice led to a decrease in the frequency of B1 cells, the precursors of CLL cells in rodents. Mechanistically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding to and antagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL cells. We also show that SPRY2 is targeted by microRNA-21, which in turn leads to increased activity of Syk and Erk in CLL cells. Taken together, these results establish SPRY2 as a critical negative regulator of BCR-mediated MAPK-Erk signaling in CLL, thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of CLL.

UR - http://www.scopus.com/inward/record.url?scp=85016118525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016118525&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-09-669317

DO - 10.1182/blood-2015-09-669317

M3 - Article

C2 - 26809508

AN - SCOPUS:85016118525

VL - 127

SP - 2310

EP - 2321

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -